Arakis Ltd

Chesterford Research Park , Little Chesterford
CB10 1XL Saffron Walden
United Kingdom

Contact

About Arakis

Arakis is an emerging specialty pharmaceutical company, with a therapeutic focus in inflammatory diseases, oncology adjunctive therapy and pain.

Product portfolio of Arakis

Product portfolio

Show all

News about Arakis

02-Nov-2005 | research and development

Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome

Sosei Co. Ltd announced that its wholly-owned subsidiary Arakis Ltd, has successfully completed Phase I single and multidose studies of AD 337, a novel ...

Read news

19-Oct-2005 | business & finance

Arakis and Vectura announce start of phase IIb trial of NVA237 for COPD

Arakis Ltd. , a wholly-owned subsidiary of Sosei Co. Ltd. , and Vectura Group plc announced that their collaborative product, NVA237 (formerly AD 237), a ...

Read news

07-Sep-2005 | research and development

Arakis commences Phase IIB trial for rheumatoid arthritis drug

Sosei Co. Ltd. announcee that its wholly-owned subsidiary Arakis Ltd ("Arakis"), has commenced a Phase IIb dose ranging study of AD 452, a novel, small ...

Read news

Show more news about Arakis

Get the life science industry in your inbox

Arakis Ltd

About Arakis

Product portfolio of Arakis

Product portfolio

News about Arakis

Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome

Arakis and Vectura announce start of phase IIb trial of NVA237 for COPD

Arakis commences Phase IIB trial for rheumatoid arthritis drug

Here you will find Arakis Ltd

Arakis Ltd